Register entryShortage reported
- Registered sites
- 1
- Active NDC listings
- 0
- Live patents
- 12
- Shortage listings
- 8
- Countries
- 1
- Base
- Switzerland
Authorisation
Registered operations
Analytical testing1Labelling1Finished drug manufacture1Packaging1sterilize1
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| InfoRLife SA | Casai, Campascio, 7748, Switzerland (CHE) | Analytical testing, Labelling, Finished drug manufacture, Packaging, sterilize | 3004537783481732753 |
Alert
Drug shortage listings
8| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Metronidazole InjectionAnti-Infective | Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82) | Current | Limited Availability | 13 Jan 202218 Aug 2026 |
| Metronidazole InjectionAnti-Infective | Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24) | Current | Limited Availability | 13 Jan 202218 Aug 2026 |
| Ropivacaine Hydrochloride InjectionAnesthesia | Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82) | Current | Available | 27 Mar 201818 Aug 2026 |
| Ropivacaine Hydrochloride InjectionAnesthesia | Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82) | Current | Available | 27 Mar 201818 Aug 2026 |
| Ropivacaine Hydrochloride InjectionAnesthesia | Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87) | Current | Available | 27 Mar 201818 Aug 2026 |
| Ropivacaine Hydrochloride InjectionAnesthesia | Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67) | Current | Unavailable | 27 Mar 201818 Aug 2026 |
| Ropivacaine Hydrochloride InjectionAnesthesia | Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66) | Current | Limited Availability | 27 Mar 201818 Aug 2026 |
| Ropivacaine Hydrochloride InjectionAnesthesia | Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87) | Current | Available | 27 Mar 201818 Aug 2026 |
Exclusivity
Patents and exclusivities
12| Patent | Product | Covers | Expiry |
|---|---|---|---|
| RE49422 | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDEnorepinephrine bitartrate | product | Feb 2035 |
| RE49443 | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDEnorepinephrine bitartrate | product | Feb 2035 |
| 10966990 | MIDAZOLAM IN 0.9% SODIUM CHLORIDEmidazolam | product | Jun 2038 |
| 10888534 | NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDEnorepinephrine bitartrate | product | Apr 2039 |
Compare
Comparable companies in Switzerland
- Ricola Ag1 site · 84 NDC
- Avyxa GmbH1 site · 29 NDC
- Bachem AG1 site · 23 NDC
- Vifor (International) AG1 site · 22 NDC
- DOTTIKON EXCLUSIVE SYNTHESIS AG1 site · 16 NDC
- HAS Healthcare Advanced Synthesis SA1 site · 11 NDC
- Cerbios-Pharma SA1 site · 9 NDC
- SINTETICA S.A.1 site · 9 NDC
- Similasan AG1 site · 7 NDC
- Swiss Caps AG1 site · 6 NDC
Enquiry
Common questions
- Is InfoRLife SA FDA approved?
- InfoRLife SA holds 1 FDA-registered establishment in Switzerland. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are InfoRLife SA's drugs manufactured?
- The FDA register lists Campascio. Registered operations: analytical testing, labelling, finished drug manufacture, packaging, sterilize.
- Are any InfoRLife SA products in shortage?
- 8 presentations are currently listed in the FDA drug shortage database under InfoRLife SA, covering Metronidazole Injection, Ropivacaine Hydrochloride Injection.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.